Our retrospective karyotype review revealed two rare recurrent translocations affecting ETV6 (TEL): t(7;12)(q36;p13) and t(7;12)(q32;p13). Five patients with a t(7;12) were from a group of 125 successfully karyotyped pediatric patients enrolled in consecutive clinical AML trials of the Dutch Childhood Leukemia Study Group over a period of 7 years. During a search of available cytogenetic databases, we found 7q and 12p abnormalities in two additional Dutch patients and in three participants in Pediatric Oncology Group trials. A del(12p) had been initially identified in four of these patients and re-examination of the original karyograms revealed a t(7;12)(q36;p13) in two instances and a probable t(7;12) in the other two. FISH confirmed the presence of a t(7;12)(q36;p13) in the latter. Most (n = 7) also had trisomy 19. The t(7;12)(q36;p13) (n = 9) was more common than the t(7;12)(q32;p13) (n = 1). These subtle translocations were found only in children 18 months of age or younger. A literature search revealed that the t(7;12) with breakpoints at 7q31-q36 and 12p12-p13 had been reported in six children with myeloid disorders and in two with acute lymphoblastic leukemia; all were 12 months of age or younger. Only two of the 17 for whom survival data were available, were alive after at least 22 months of continuous complete remission. Our findings suggest that ETV6 rearrangements due to a t(7;12) may play an adverse role in myeloid disorders in children 18 months of age or younger. Therefore, children in this age group with myeloid disorders should be screened for both MLL and ETV6 rearrangements. Leukemia (2001) 15, 915-920.
Introduction
Abnormalities of the ETV6 gene at 12p13 are found in a wide range of myeloid and lymphoid disorders. The t(12;21)(p13;q22), which results in a fusion of ETV6 and CBFA2, is the most common translocation in pediatric patients with acute lymphoblastic leukemia (ALL), and typically occurs in patients between 1 and 10 years of age. 1 In pediatric patients with myeloid disorders, recurrent translocations involving ETV6 have been found in relatively few instances. [2] [3] [4] During a review of karyotypes of 125 pediatric patients treated for acute myeloid leukemia (AML) in consecutive trials of the Dutch Childhood Leukemia Study Group (DCLSG), two patients were found to have a t(7;12)(q36;p13), one was found to have a t(7;12)(q32;p13), and two others were found to have a del (12) (p13) and a +19. Because a relatively high number of abnormalities involving 12p13, and possibly ETV6, were found in this group, we re-examined the karyotype databases available to us to determine whether a subtle t(7;12) is present in a subpopulation of pediatric patients with myeloid disorders.
Materials and methods
The 7q and 12p abnormalities were originally identified during the review of cytogenetic data of 130 patients who were between 3 weeks and 17 years of age and were enrolled in consecutive clinical AML trials of the DCLSG over a period of 7 years. We also searched for additional patients with these cytogenetic abnormalities in archived karyotype data of other pediatric patients who had been treated for AML on DCLSG protocols or had been enrolled in AML studies administered by the Pediatric Oncology Group (POG).
Cytogenetic studies had been performed with banded metaphase chromosomes (GTG/QFA/RFA) obtained from bone marrow, peripheral blood, or both by using standard short-term culturing techniques. The original karyograms of the patients with abnormalities of 7q, 12p or both were re-evaluated.
Fixed chromosome suspensions from three Dutch patients were available for dual-color fluorescence in situ hybridization (FISH) analysis which was performed according to the method of Hagemeijer et al. 5 We used ETV6 cosmid probes that spanned most of the gene from exon 1 to exon 8 (tel-179A6 -15A4 -50F4 -132B11 -54D5 -cen), 3 and subtelomeric probes specific for 7q (2000a5) and for 12p (9015). 6 Also available as probes in this study were a cosmid that contained the entire ENOS gene at 7q36 and 4.5-kb sequences that flanked this gene; 7 the CEPH YAC 965FCF12 (locus D7S550; size 160 kb), which is also localized to 7q36; and an alpha satellite probe for the centromeric region of chromosome 7 (p7t1). We performed FISH with the Vysis LSI PML/RARA probe to detect a PML-RARA rearrangement in one patient (Vysis, Downers Grove, IL, USA). When sufficient sample material was available, we evaluated MLL status by performing FISH 8 or Southern blot analysis. 9 All karyotype and FISH findings were described according to the guidelines of the International System for Human Cytogenetic Nomenclature.
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Results and discussion
The original and revised karyotypes after our re-examination of the karyograms and FISH analyses are shown in Table 1 . Of the 130 pediatric patients who had been enrolled in consecutive clinical AML trials of the DCLSG, 125 had been successfully karyotyped. Five (4%) had been reported to have Table 1 Original and revised karyotypes of 10 children from the present study and of eight with t( 46,XY,inv(2)(p11q13),add(7)(q36),del (12) 46,XY,inv(2)(p11q13),t(7;12)(q36;p13),der (16) 12p13 abnormalities: two patients had a t(7;12)(q36;p13) ( Table 1 , patients 1 and 4), one had a t(7;12)(q32;p13) (patient 10), and two others had a del(12)(p13) (patients 2 and 3). Patients 2, 3, 4 and 10 also had +19 as an additional abnormality. FISH studies confirmed the t(7;12)(q36;p13) in patient 1 and the breakpoint in ETV6 was shown to be located in intron 1 since the signals for probes 179A6 and 15A4 were located on the der(7)t(7;12). Hybridization of 7q and 12p subtelomeric probes revealed that a t(7;12)(q36;p13) was also present in the leukemic cells of patients 2 and 3, orginally identified as having a del(12)(p13). In both instances, a breakpoint was also located in intron 1 of ETV6. However, in patient 2, the translocation was accompanied by a deletion of the region distal to exon 2 of ETV6 as shown by the absence of signals for 179A6 and 15A4 on both derivative chromosomes.
Because of a lack of sufficient material, FISH with additional chromosome 7-specific probes was only performed on samples from patient 3. The ENOS gene at 7q36 7 did not appear to be involved in the translocation because the cosmid probe containing the entire ENOS gene and 4.5-kb flanking sequences hybridized only to the der(7). However, the CEPH YAC 965FCF12 did span the translocation breakpoint and hybridized to both the der(7) and the der(12) (Figure 1 ).
Figure 1
Inverted DAPI image of a spread of metaphase chromosomes from patient 3 with a t(7;12)(q36;p13). CEPH YAC 965FCF12 (red) hybridized to the der(7), der (12) , and the normal homologue of chromosome 7. The alpha satellite probe for the centromeric region of chromosome 7 (p7t1) (green) hybridized to both the normal homologue of chromosome 7 and the der(7).
The original diagnosis for patient 3 was an M3 variant of AML but no PML-RARA rearrangement was detected by FISH. Although there is a high incidence of 11q23/MLL abnormalities in children who are 18 months of age or younger and have AML, 11 we detected no changes in the MLL gene in those patients' samples that were subjected to additional FISH (patients 2 and 3) or Southern blot analysis (patient 4).
Our re-examination of the other karyotype databases revealed that a t(7;12)(q36;p13) was present in five additional patients. Two had been treated by earlier DCLSG AML protocols (patients 5 and 6); patient 5 has been previously reported by Hagemeijer et al. 12 The other three (patients 7, 8 and 9) had participated in POG protocols. Patient 7 had been erroneously reported to have a t(7;12)(p36;p13) due to a typographical error in the description of the arm of chromosome 7.
13 Patient 8 was initially reported to have a del(12)(p12), 13 and patient 9 had a del(12)(p12-13). It should be noted that a +19 was also present in patients 6, 7 and 8. Table 2 gives the clinical characteristics of nine children with a t(7;12)(q36;p13) (patients 1-9) and one patient with a t(7;12)(q32;p13) (patient 10) at the time of diagnosis. All 10 patients with a t (7;12) were between the ages of 3 and 18 months at the time of diagnosis. Nine children had AML, and, because of the low number of blast cells at diagnosis, patient 1 was finally classified as having RAEB-t. Seven patients (patients 1-6, 10) had been treated according to DCLSG AML protocols, two (patients 7 and 8) had been treated according to POG-8821, and one (patient 9) had been treated according to POG-9421. Five of the eight patients with organomegaly also had central nervous system involvement. Disease in only one child (patient 1) (a recipient of a bone marrow transplant) Leukemia has not relapsed and the first remission has lasted at least 22 months. Six patients died of leukemia, one died of leukemia and an infection, one died of an infection, and another died of treatment-related toxic effects.
The patients with a t(7;12), identified during the initial review of karyotypes of patients enrolled in consecutive DLSCG AML trials, were only 4% (5/125) of the total number of those successfully karyotyped, but they represented 18.5% (5/27) of those patients between 0 and 18 months of age, and 21.7% (5/23) of those in this age group without Down syndrome. We were unable to perform a similar study on the frequency of this translocation in patients treated in the POG studies since we had reviewed only the final chromosome analysis reports and not the actual karyograms. Consequently, an analysis of these data would have underestimated the frequency of the subtle t(7;12).
Our results suggest that the t(7;12)(q36;p13) is more common than the t(7;12)(q32;p13) in childhood AML and can also be found in RAEB-t. A literature search revealed a t(7;12)(q36;p13) identified in two infants with AML (Tables 1  and 2 , patients 11 and 12), 2,3 two with ALL (patients 13 and 14), 14, 15 and one with MDS (patient 15). 2 A t(7;12)(q32;p13) has been found in two infants with AML (patients 16 and 17), 4 and a third (patient 18) had a t(7;12)(q31;p12). 16 When these published findings and those from the present study are combined, the age at the time of diagnosis ranged from 1 to 18 months, and only two of the 17 patients for whom survival data were available are known to have survived ( Table 2 , patients 1 and 17). These results suggest that the t(7;12) is associated with hematologic malignancies in children who are 18 months of age or younger. These children have a poor outcome, but because various treatment regimens have been used, the relationship among the t(7;12), young age, and poor outcome needs to be confirmed by additional studies.
As demonstrated in our study, the t(7;12) is not always easily identified, and in two patients the abnormality was only confirmed after additional FISH studies. Likewise, three of the reported cases (Table 1, patients 11, 12, 15) were only clarified after the authors had performed additional FISH analyses. [2] [3] [4] However, seven of our patients and six of those reported with the t(7;12) also had trisomy 19 ( Table 1) . The presence of trisomy 19 in infants with hematologic disorders thus warrants the use of FISH for further examination for the t(7;12).
In three instances of the t(7;12)(q36;p13) in our series, the breakpoints were located in intron 1 of ETV6. A similar breakpoint was also identified by FISH in another infant with this translocation (Table 1, patient 11) . 3 A breakpoint in intron 2 of ETV6 was present in two other infants with this abnormality (Tables 1, patients 12 and 15) . 2 Likewise, ETV6 was involved in two reported cases of t(7;12)(q32;p13) ( Table 1, patients 16  and 17) : one with a breakpoint in intron 1 and the other with a breakpoint either in intron 1 or just upstream of exon 1. 4 These translocation breakpoints in ETV6 are similar to those of other ETV6 translocations found in patients with AML. These translocations include the t(12;22)(p13;q11), in which the MN1 gene fuses with the region encoding the DNA binding domain of ETV6;
17 the t(6;12)(q23;p13), in which the STL gene fuses with this region; 18 and the t(4;12)(q11-q12;p13), in which the BTL gene fuses with this region. 19 In our study, the discovery of a deletion of the distal region, up to intron 1, of the ETV6 allele involved in the t(7;12) in patient 2 suggests either that the fusion product encoded by the der(12)t(7;12) is an important factor in leukemogenesis or that no fusion gene is created and that disruption of the ETV6 gene is involved. Slater et al. 16 An important finding in the present study is that the CEPH YAC 965FCF12 hybridized with both derivative chromosomes in a sample from patient 3 with a t(7;12)(q36;p13). Unfortunately, we had no additional material from this patient for molecular studies. An additional FISH study on material from patient 11 in Table 1 using PAC H-DJ1121A15 for region 7q36 (for further details see http://www.genet.sickkids. on.ca/chromosome7) showed a split signal on the der(7) and der(12) (personal communication Prof. Anne Hagemeijer, September 2000). These two probes should be tested on samples from patients with similar translocations, because the results of such hybridizations could yield clues as to the identity of the possible ETV6 fusion partner on 7q36.
Infant acute leukemia is associated with translocations involving the MLL gene at 11q23. 20, 21 Approximately 80% of infants with ALL have 11q23/MLL abnormalities, whereas only 60% of infants with AML appear to have similar abnormalities. 4, 22, 23 The MLL rearrangement was absent in three of our patients with a t(7;12)(q36;p13) whose samples were sufficient for further analysis and in the two patients with t(7;12)(q32;p13) described by Satake et al 4 ( Table 1, patients 16 and 17). These findings suggest that in children who are 18 months of age or younger and have germline MLL alleles, translocations involving ETV6 are quite common. Two patients, under the age of 12 months, were reported to have ALL ( Table 2 , patients 13 and 14). 14,15 A Southern blot screening for ETV6 rearrangements in 69 children less than 1 year of age with this disorder had revealed no abnormalities. 24 However, this was probably because the combination of probe and restriction enzyme digest used in that study was designed to detect Ͼ95% of cases with ETV6-CBFA2 fusion, involving breakpoints between exons 5 and 6 of ETV6, proximal to that found for the t(7;12).
Like MLL, ETV6 has numerous translocation partners and is rearranged in myeloid and lymphoid malignancies. 25 In addition, abnormalities of both these genes can arise in utero and lead to postnatal acute leukemia. 26, 27 MLL translocations found in secondary leukemia resulting from treatment with topoisomerase II inhibitors and those MLL translocations found in infant acute leukemia have breakpoints clustered in the same region; such clustering suggests that environmental sources of these inhibitors may play a role in the development of congenital leukemia with these abnormalities. 28 Other environmental factors could also be responsible for the involvement of ETV6 in infant leukemia.
Immediately before our paper was submitted to Leukemia, Tosi et al 29 published the findings of their FISH study of ETV6 rearrangements in 23 young children with leukemia. These cases were selected from available cytogenetic databases on the basis of age younger than 20 months at the time of diagnosis and the presence of additional copies of chromosome 8, 19, or both in leukemic cells. In addition, cases reported to have 7q or 12p abnormalities were considered. Five patients with myeloid malignancies, including two whose leukemic cell karyotypes have been previously reported, 2 and two patients with ALL had evidence of ETV6 rearrangements with breakpoints clustered upstream of exons 3 to 5; these breakpoints are similar to those found in our study. Involvement of chromosome band 7q36 in translocations was also predominant in their group of patients: 7q36 was involved in translocations in six patients, and 7q22 was involved in one translocation. FISH also revealed that at least one patient had a different breakpoint in 7q36; this finding suggests that several different genes in this region may be involved in leukemogenesis. Interestingly, like us, they found that ETV6 sequences were deleted from the der(7) in one patient with AML and a t(7;12)(q36;p13).
Our findings and those of Tosi et al 29 provide evidence that ETV6 plays a role in the development of leukemia in children who are 18 months of age or younger. However, the true incidence of ETV6 involvement in these young children with malignancies can be ascertained only by systematic screening for rearrangements of both ETV6 and MLL
